Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States.
Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine.
Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022.
The company was incorporated in 2008 and is headquartered in Seattle, Washington.
On December 19, 2023, Impel Pharmaceuticals Inc, along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in theU. S.
Bankruptcy Court for the Northern District of Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 3, 24 | 0.00 Increased by +100.00% | -0.39 Increased by +100.00% |
| Mar 22, 24 | 0.00 Increased by +100.00% | -0.21 Increased by +100.00% |
| Nov 14, 23 | -0.58 Increased by +55.73% | -0.36 Decreased by -61.11% |
| Aug 18, 23 | -0.31 Increased by +71.56% | -0.65 Increased by +52.31% |
| May 12, 23 | -1.27 Decreased by -8.55% | -0.90 Decreased by -41.11% |
| Mar 24, 23 | -0.97 Increased by +9.35% | -1.11 Increased by +12.61% |
| Nov 14, 22 | -1.31 Decreased by -5.65% | -1.00 Decreased by -31.00% |
| Aug 15, 22 | -1.09 Increased by +0.91% | -1.05 Decreased by -3.81% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 5.02 M Increased by +62.98% | -13.81 M Increased by +66.27% | Decreased by -275.01% Increased by +79.30% |
| Jun 30, 23 | 6.58 M Increased by +134.89% | -7.36 M Increased by +75.00% | Decreased by -111.74% Increased by +89.36% |
| Mar 31, 23 | 4.37 M Increased by +148.55% | -38.63 M Decreased by -23.75% | Decreased by -883.60% Increased by +50.21% |
| Dec 31, 22 | 5.01 M Increased by +767.94% | -36.31 M Decreased by -46.76% | Decreased by -725.08% Increased by +83.09% |
| Sep 30, 22 | 3.08 M Increased by +3.29 K% | -40.95 M Decreased by -63.68% | Decreased by -1.33 K% Increased by +95.17% |
| Jun 30, 22 | 2.80 M Increased by +N/A% | -29.43 M Decreased by -90.08% | Decreased by -1.05 K% Decreased by N/A% |
| Mar 31, 22 | 1.76 M Increased by +N/A% | -31.22 M Decreased by -176.48% | Decreased by -1.77 K% Decreased by N/A% |
| Dec 31, 21 | 577.00 K Increased by +N/A% | -24.74 M Decreased by -76.43% | Decreased by -4.29 K% Decreased by N/A% |